Law Firm · Petitioner PracticeVICP Petitioner PracticeLast verified
Cases filed
1
Comp rate
100%
Total awarded
$70K
Tenure
2024
⚠Heads up: The case docket, statistics, and overview below are compiled from AI-extracted data. Specific figures (case counts, awards, outcomes) may contain errors. Verify with the firm directly or with source court records before relying on them.
The Scanlon Group is a U.S. law firm whose name appears on 1 petition in the National Vaccine Injury Compensation Program. The single recorded filing dates to 2024; compensation rate of 100%. Cases on file have produced $70K in total awards. The attorneys appearing on this firm's docket include John Scanlon.
AI-generated overview · may contain errors. Verify details with the firm directly before relying on them.
Frequently asked questions about The Scanlon Group
Answers built from this firm's public case docket.
How do I find a good VICP lawyer?
Most petitioners hire counsel because the program's evidentiary burden, expert-witness requirements, and procedural rules are complex. Reasonable attorney fees in VICP cases are paid by the program — not by the petitioner — under 42 U.S.C. § 300aa-15(e)(1), so engaging counsel does not reduce a successful petitioner's recovery. Research The Scanlon Group's case history below.
How many VICP cases has The Scanlon Group filed?
The Scanlon Group has filed 1 petitions in the U.S. Vaccine Injury Compensation Program with publicly-available decisions, between 2024 and 2024.
What is The Scanlon Group's compensation rate?
The Scanlon Group's overall compensation rate across 1 VICP cases is 100% (1 compensated).
How much has The Scanlon Group won in VICP cases?
Cases filed by The Scanlon Group have resulted in $70K in total compensation awards from the U.S. Vaccine Injury Compensation Program (visible-in-public-decisions only).
What kinds of vaccine injury cases does The Scanlon Group handle?
Based on the cases on file, The Scanlon Group's practice includes Transverse myelitis, among other vaccine-related conditions.